Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Rain Oncology Inc.: The Board adopted an amendment and restatement of the Bylaws to enhance procedural and disclosure requirements for stockholder proposals and director nominations, align with Rule 14a-19 under the Exchange Act, update various provisions per the DGCL, and incorporate ministerial, clarifying and confor (effective 2023-02-15).
- Change
- bylaw amendment
- Effective
- 2023-02-15
Exact text from the filing
On February 15, 2023, the Board of Directors (the “Board”) of Rain Oncology Inc., a Delaware corporation (the “Company”), adopted an amendment and restatement of the Company’s Second Amended and Restated Bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date, in order to, among other things: • Enhance procedural and disclosure requirements related to business proposals and director nominations submitted by stockholders, including to align with recently adopted Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and reflect certain other administrative changes, including: • Requiring additional background information and disclosures regarding proposing stockholders, proposed nominees and business, and other persons related to proposing stockholders; • Requiring any stockholder submitting a notice of director nomination to make a representation as to whether such stockholder intends to solicit proxies in suppo
View on SEC.gov